Three insights from Dr. Byrne:
On the potential of AI: “If you use CADe, or computer-aided detection, as an example, there are several studies that show that this AI-type tool improves … the adenoma detection rate, or in other words, looking for precancerous polyps.”
On potential applications for AI: “As I hope and as I expect in the next few years, it is mandated that we reach a certain minimum threshold for performance. … If we are mandated to reach an ADR of say, 40 percent … if you are not reaching that level, by whatever means, maybe you won’t be reimbursed and/or your privileges for that procedure will not be renewed by your healthcare institution.”
On the FDA-approval process: “I think, given what has happened in Europe and looking at the huge amount of work that is being published in the journals and the clinical trials that are listed on the clinicaltrials.gov website, I think it’s only a matter of short time that the FDA will approve some of these AI devices.”
Read the entire piece on the Next Services website here.
More articles on healthcare:
Top-paying jobs in 2020 — Surgeons are No. 1
The state of ASCs in June 2020: 10 observations on supply chain, payers, staffing & future growth
Optum leads $26M funding round for digital therapeutics startup
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.